menu
    • menu

    List of NDC API details of Deucravacitinib Active Pharmaceutical Ingredient listed on PharmaCompass.com

    Client Email Product
    Farmhispania Deucravacitinib

    Virtual Booth

    Contact Supplier

    Moehs Deucravacitinib

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    AMI Deucravacitinib

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    10

    API Suppliers

    API Suppliers

    0

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    2

    NDC API

    NDC API

    0

    VMF

    NDC API

    10

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 111,288

    MARKET PLACE

    1

    API

    1

    FDF

    1INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    3

    FDF Dossiers

    FDF Dossiers

    1

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    1

    Canada

    Canada

    1

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    15DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    3

    US Patents

    1

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    2

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    31

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    1,499,644

    Annual Reports

    178

    Finished Drug Prices

    NA

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Bms-986165, 1609392-27-9, Tyk2-in-4, Bms986165, Deucravacitinib [usan], N0a21n6rau
    Molecular Formula
    C20H22N8O3
    Molecular Weight
    425.5  g/mol
    InChI Key
    BZZKEPGENYLQSC-FIBGUPNXSA-N
    FDA UNII
    N0A21N6RAU
    Deucravacitinib
    Deucravacitinib is under investigation in clinical trial NCT04772079 (A Study to Evaluate the Drug Levels, Efficacy and Safety of BMS-986165 in Adolescent Participants With Moderate to Severe Plaque Psoriasis).
    1 2D Structure

    Deucravacitinib

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide
    2.1.2 InChI
    InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3
    2.1.3 InChI Key
    BZZKEPGENYLQSC-FIBGUPNXSA-N
    2.1.4 Canonical SMILES
    CNC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4
    2.1.5 Isomeric SMILES
    [2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4
    2.2 Other Identifiers
    2.2.1 UNII
    N0A21N6RAU
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Bms-986165

    2.3.2 Depositor-Supplied Synonyms

    1. Bms-986165

    2. 1609392-27-9

    3. Tyk2-in-4

    4. Bms986165

    5. Deucravacitinib [usan]

    6. N0a21n6rau

    7. 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-n-(trideuteriomethyl)pyridazine-3-carboxamide

    8. Deucravacitinib (usan)

    9. Sotyktu

    10. Unii-n0a21n6rau

    11. Deucravacitinib [inn]

    12. Deucravacitinib [jan]

    13. Chembl4435170

    14. Deucravacitinib [who-dd]

    15. Schembl20520348

    16. Gtpl10432

    17. Ex-a3154

    18. Bdbm50507816

    19. Mfcd31715455

    20. Nsc825520

    21. S8879

    22. Tyk2-in-4(bms986165)

    23. Who 11342

    24. At18623

    25. Nsc-825520

    26. Compound 11 [pmid: 31318208}

    27. Ncgc00687789-01

    28. Ac-31543

    29. Hy-117287

    30. Cs-0065044

    31. D11817

    32. 3-pyridazinecarboxamide, 6-((cyclopropylcarbonyl)amino)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)-

    33. 3-pyridazinecarboxamide, 6-((cyclopropylcarbonyl)amino]-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)n-(methyl-d3)-

    34. 6-((cyclopropylcarbonyl)amino)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(2h3)methyl-3-pyridazine-carboxamide

    35. 6-((cyclopropylcarbonyl)amino]-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-((2h3)methyl)pyridazine-3-carboxamide

    36. 6-[(cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl]amino]-n-(methyl-d3)-3-pyridazinecarboxamide

    2.4 Create Date
    2018-10-30
    3 Chemical and Physical Properties
    Molecular Weight 425.5 g/mol
    Molecular Formula C20H22N8O3
    XLogP31.2
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count7
    Exact Mass425.20031683 g/mol
    Monoisotopic Mass425.20031683 g/mol
    Topological Polar Surface Area136 Ų
    Heavy Atom Count31
    Formal Charge0
    Complexity648
    Isotope Atom Count3
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of psoriasis

    Treatment of Systemic Lupus Erythematosus (SLE)

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Dermatologic Agents

    Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)

    Protein Kinase Inhibitors

    Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

    5.2 ATC Code

    L - Antineoplastic and immunomodulating agents

    L04 - Immunosuppressants

    L04A - Immunosuppressants

    L04AA - Selective immunosuppressants

    L04AA56 - Deucravacitinib

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1716402600,"product":"DEUCRAVACITINIB PRIMARY STANDARD (RND PURPOSE)","address":"2ND FLOOR, CHINUBHAI CENTRE,","city":"AHMEDABAD, GUJARAT","supplier":"CURIA","supplierCountry":"SPAIN","foreign_port":"MADRID","customer":"INTAS PHARMACEUTICALS","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.9","unit":"GMS","unitRateFc":"5000","totalValueFC":"4605","currency":"USD","unitRateINR":"426494.7","date":"23-May-2024","totalValueINR":"383845.22","totalValueInUsd":"4605","indian_port":"Ahmedabad Air","hs_no":"29349990","bill_no":"3622229","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"MADRID","supplierAddress":"PARQUE TECNOLOGICO DE BOECILLO, PARCELA 105, 47151 BOECILLO VALLADOLID,SPAIN VALLADOLID, , Spain Spain","customerAddress":"2ND FLOOR, CHINUBHAI CENTRE,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1716402600,"product":"DEUCRAVACITINIB PRIMARY STANDARD (RND PURPOSE)(FOC SHIPMENT)","address":"2ND FLOOR, CHINUBHAI CENTRE,","city":"AHMEDABAD, GUJARAT","supplier":"CURIA","supplierCountry":"SPAIN","foreign_port":"MADRID","customer":"INTAS PHARMACEUTICALS","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.1","unit":"GMS","unitRateFc":"100","totalValueFC":"10.2","currency":"USD","unitRateINR":"8529.9","date":"23-May-2024","totalValueINR":"852.99","totalValueInUsd":"10.2","indian_port":"Ahmedabad Air","hs_no":"29349990","bill_no":"3622229","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"MADRID","supplierAddress":"PARQUE TECNOLOGICO DE BOECILLO, PARCELA 105, 47151 BOECILLO VALLADOLID,SPAIN VALLADOLID, , Spain Spain","customerAddress":"2ND FLOOR, CHINUBHAI CENTRE,"}]
    23-May-2024
    23-May-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    US Patents

    read-more
    read-more

    01

    BRISTOL

    DEUCRAVACITINIB

    arrow
    Luxepack
    Not Confirmed

    BRISTOL

    United Kingdom
    arrow
    Luxepack
    Not Confirmed

    Patent Expiration Date : 2033-11-07

    DEUCRAVACITINIB

    US Patent Number : 10000480

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 214958

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2033-11-07

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    BRISTOL

    DEUCRAVACITINIB

    arrow
    Luxepack
    Not Confirmed

    BRISTOL

    United Kingdom
    arrow
    Luxepack
    Not Confirmed

    Patent Expiration Date : 2033-11-07

    DEUCRAVACITINIB

    US Patent Number : RE47929

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 214958

    Patent Use Code : U-3434

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2033-11-07

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    BRISTOL

    DEUCRAVACITINIB

    arrow
    Luxepack
    Not Confirmed

    BRISTOL

    United Kingdom
    arrow
    Luxepack
    Not Confirmed

    Patent Expiration Date : 2033-11-07

    DEUCRAVACITINIB

    US Patent Number : 11021475

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 214958

    Patent Use Code : U-3434

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2033-11-07

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Deucravacitinib Manufacturers | Traders | Suppliers

    Deucravacitinib Manufacturers, Traders, Suppliers 1
    53

    We have 2 companies offering Deucravacitinib

    Get in contact with the supplier of your choice:

    1. Hovione
    2. SK Biotek
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search